glycine has been researched along with Leukemia, Myeloid, Acute in 79 studies
Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Excerpt | Relevance | Reference |
---|---|---|
"Ivosidenib 500-mg QD has favorable pharmacokinetic and pharmacodynamic profiles in patients with advanced hematologic malignancies with an IDH1 mutation." | 9.34 | Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. ( Agresta, SV; Attar, EC; Dai, D; de Botton, S; DiNardo, CD; Fan, B; Lemieux, I; Liu, G; Liu, H; Stein, E; Yang, H, 2020) |
"To the best of our knowledge, this is the first reported case of myopericarditis and cardiogenic shock related to ivosidenib use." | 9.05 | Ivosidenib induction therapy complicated by myopericarditis and cardiogenic shock: A case report and literature review. ( Chen, A; Hernandez Burgos, P; Patel, J, 2020) |
"We report a case of differentiation syndrome in a patient receiving the IDH1 inhibitor ivosidenib, with skin biopsy showing isocitrate dehydrogenase (IDH) R132H-mutated leukemia cutis." | 7.96 | Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation. ( Chase, M; Fernandez-Pol, S; Kwong, BY; Novoa, RA; Tabata, MM, 2020) |
"Reactive oxygen species (ROS)-specific mechanisms of drug resistance were explored in paraquat (PQ)-resistant acute myelogenous leukemia cell (OCI/AML-2) sublines." | 7.70 | Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines. ( Choi, CH; Chung, MH; Jeong, JH; Kim, HS; Kim, MS; Kweon, OS; Lee, TB; Lim, DY; Min, YD; Rha, HS; You, HJ, 2000) |
"Ivosidenib 500-mg QD has favorable pharmacokinetic and pharmacodynamic profiles in patients with advanced hematologic malignancies with an IDH1 mutation." | 5.34 | Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. ( Agresta, SV; Attar, EC; Dai, D; de Botton, S; DiNardo, CD; Fan, B; Lemieux, I; Liu, G; Liu, H; Stein, E; Yang, H, 2020) |
"To the best of our knowledge, this is the first reported case of myopericarditis and cardiogenic shock related to ivosidenib use." | 5.05 | Ivosidenib induction therapy complicated by myopericarditis and cardiogenic shock: A case report and literature review. ( Chen, A; Hernandez Burgos, P; Patel, J, 2020) |
"We report a case of differentiation syndrome in a patient receiving the IDH1 inhibitor ivosidenib, with skin biopsy showing isocitrate dehydrogenase (IDH) R132H-mutated leukemia cutis." | 3.96 | Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation. ( Chase, M; Fernandez-Pol, S; Kwong, BY; Novoa, RA; Tabata, MM, 2020) |
"The cytotoxic effects of ixazomib treatment were analyzed in human acute myelogenous leukemia (AML) cell lines and primary AML samples expressing wild-type or mutated NPM1 (NPMc(+))." | 3.83 | Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species. ( Garcia, JS; Huang, M; Medeiros, BC; Mitchell, BS, 2016) |
"Reactive oxygen species (ROS)-specific mechanisms of drug resistance were explored in paraquat (PQ)-resistant acute myelogenous leukemia cell (OCI/AML-2) sublines." | 3.70 | Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines. ( Choi, CH; Chung, MH; Jeong, JH; Kim, HS; Kim, MS; Kweon, OS; Lee, TB; Lim, DY; Min, YD; Rha, HS; You, HJ, 2000) |
" These findings support the dosing of ivosidenib or enasidenib in combination with intensive chemotherapy for the treatment of patients with newly diagnosed mIDH1/2 AML." | 3.11 | Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia. ( Almon, C; Chen, Y; Cooper, M; Fan, B; Hossain, M; Hua, L; Nabhan, S; Yang, H; Yin, F, 2022) |
" Given their effectiveness as single agents in mIDH1/2 relapsed or refractory acute myeloid leukemia (AML), this phase 1 study evaluated the safety and efficacy of ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed mIDH1/2 AML." | 3.01 | Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. ( Almon, C; Choe, S; Cooper, M; DiNardo, CD; Döhner, H; Fan, B; Fathi, AT; Franovic, A; Frattini, MG; Hua, L; Kantarjian, HM; Lersch, F; Löwenberg, B; McCloskey, JK; Mims, AS; Nabhan, S; Odenike, O; Ossenkoppele, GJ; Patel, PA; Pollyea, DA; Pratz, KW; Roshal, M; Savona, MR; Seet, CS; Stein, AS; Stein, EM; Stone, RM; Tallman, MS; Wang, H; Winer, ES; Wu, B, 2021) |
"Ivosidenib is a once daily (q." | 3.01 | Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies. ( Fan, B; Jiang, X; Kapsalis, S; Kleijn, HJ; Le, K; Liu, G; Liu, H; Poland, B; Wada, R; Yang, H, 2021) |
"Tosedostat is a selective oral aminopeptidase inhibitor, which in phase I/II trials showed acceptable toxicity and encouraging efficacy." | 3.01 | A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. ( Ariti, C; Burnett, A; Clark, RE; Copland, M; Dennis, M; Greaves, P; Hemmaway, C; Hills, R; Russell, N; Severinsen, MT; Thomas, I, 2021) |
"Ivosidenib (AG-120) is an oral, targeted agent that suppresses production of the oncometabolite 2-hydroxyglutarate via inhibition of the mutant isocitrate dehydrogenase 1 (IDH1; mIDH1) enzyme." | 2.94 | Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. ( Agresta, SV; Altman, JK; Arellano, ML; Attar, EC; Choe, S; Dai, D; de Botton, S; DiNardo, CD; Donnellan, W; Erba, HP; Fan, B; Fathi, AT; Hickman, D; Kantarjian, HM; Kapsalis, SM; Liu, H; Mannis, GN; Mims, AS; Pollyea, DA; Prince, GT; Roboz, GJ; Stein, AS; Stein, EM; Stone, RM; Tallman, MS; Uy, GL; Wang, H; Watts, JM; Wu, B; Yen, KE; Zhang, V, 2020) |
" A phase I trial of the second-generation proteasome inhibitor ixazomib in combination with MEC (mitoxantrone, etoposide, and cytarabine) was conducted in patients with R/R AML." | 2.90 | A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. ( Advani, AS; Caimi, P; Carew, J; Carraway, H; Chan, R; Cooper, B; de Lima, M; Elson, P; Gerds, A; Hamilton, B; Kalaycio, M; Little, J; Maciejewski, J; Malek, E; Miron, A; Mukherjee, S; Nazha, A; Pink, J; Sekeres, MA; Sobecks, R; Tomlinson, B; Unger, A; Visconte, V; Wei, W, 2019) |
"Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1." | 2.87 | Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. ( Agresta, S; Altman, JK; Arellano, ML; Attar, EC; Choe, S; Collins, RH; Dai, D; de Botton, S; DiNardo, CD; Donnellan, W; Erba, HP; Fan, B; Fathi, AT; Foran, JM; Goldwasser, M; Kantarjian, HM; Kapsalis, SM; Liu, H; Mannis, GN; Mims, AS; Pigneux, A; Pollyea, DA; Prince, GT; Roboz, GJ; Sekeres, MA; Slack, JL; Stein, AS; Stein, EM; Stone, RM; Stuart, RK; Swords, R; Tallman, MS; Traer, E; Uy, GL; Wang, H; Willekens, C; Wu, B; Yang, H; Yen, KE; Zhang, V, 2018) |
"To identify the maximum-tolerated dose (MTD) and to evaluate the antileukemic activity of tosedostat (formerly CHR-2797), an orally bioavailable aminopeptidase inhibitor." | 2.75 | Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. ( Bone, E; Burnett, AK; Davies, F; Dierickx, D; Dührsen, U; Flores, N; Hooftman, L; Jenkins, C; Krug, U; Löwenberg, B; Morgan, G; Müller-Tidow, C; Ossenkoppele, GJ; Richardson, AF; Sonneveld, P; Zachée, P; Zweegman, S, 2010) |
"Ivosidenib is a promising, most probably practice changing, new drug for the treatment of IDH1-mutated AML." | 2.66 | Evaluating ivosidenib for the treatment of acute myeloid leukemia. ( Donker, ML; Ossenkoppele, GJ, 2020) |
"The prognosis of adult acute myeloid leukemia (AML) remains poor, with the long-term survival rate less than 50%." | 2.61 | Venetoclax-based therapies for acute myeloid leukemia. ( DiNardo, C; Guerra, VA; Konopleva, M, 2019) |
" This orally bioavailable agent has shown promising activity in vitro and in early clinical trials for patients with relapsed/refractory AML." | 2.50 | Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia. ( Cortes, JE; DiNardo, CD, 2014) |
"Acute myeloid leukemia is most often diagnosed in patients older than 60 years of age." | 2.48 | Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial. ( Mathisen, MS; Ravandi, F, 2012) |
"A majority of patients with acute myeloid leukemia (AML) will relapse after achieving complete remission." | 2.48 | The prevalent predicament of relapsed acute myeloid leukemia. ( Szer, J, 2012) |
"Ixazomib (IXA) is an orally available proteasome inhibitor, with an improved safety profile compared to Bortezomib (BTZ)." | 1.62 | Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. ( Cloos, J; Jansen, G; Kaspers, GJL; Kwidama, ZJ; Roeten, MSF; Segerink, WH; Ter Huizen, G; van Meerloo, J; Zweegman, S, 2021) |
"Develop a physiologically based pharmacokinetic (PBPK) model of ivosidenib using in vitro and clinical PK data from healthy participants (HPs), refine it with clinical data on ivosidenib co-administered with itraconazole, and develop a model for patients with acute myeloid leukemia (AML) and apply it to predict ivosidenib drug-drug interactions (DDI)." | 1.56 | Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ( Fan, B; Ke, A; Le, K; Prakash, C; Yang, H, 2020) |
"Tosedostat is an orally administered metalloenzyme inhibitor with antiproliferative and antiangiogenic activity against hematological and solid human cancers." | 1.56 | Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML. ( Candoni, A; Clavio, M; Dennis, M; Giannini, B; Gibellini, D; Gilkes, A; Isidori, A; Loscocco, F; Mianulli, AM; Musuraca, G; Navari, M; Piccaluga, PP; Rocchi, M; Sensi, A; Visani, G; Zuffa, E, 2020) |
"Acute and chronic myeloid leukemia are initiated and sustained by a small, self-renewing population of leukemic stem cells, which produce progeny of a heterogeneous population of progenitor cells." | 1.40 | Stromal cell derived factor-1 (CXCL12) chemokine gene variant in myeloid leukemias. ( Bahaa, NM; El-Ghany, HM; El-Saadany, ZA; Hussien, SM; Ibrahim, NY, 2014) |
"We analyzed 2502 patients with acute myeloid leukemia at diagnosis for NRAS mutations around the hot spots at codons 12, 13, and 61 and correlated the results to cytomorphology, cytogenetics, other molecular markers, and prognostic relevance of these mutations." | 1.33 | Implications of NRAS mutations in AML: a study of 2502 patients. ( Bacher, U; Haferlach, T; Kern, W; Schnittger, S; Schoch, C, 2006) |
"Two patients of acute myeloblastic leukemia (M2) with post-transfusional hepatitis (non-A, non-B) were treated with alpha-IFN and high-dose SNMC before allogeneic bone marrow transplantation." | 1.28 | [Allogeneic bone marrow transplantation after the treatment of alpha-IFN and high-dose SNMC in two cases of acute myeloblastic leukemia with post-transfusional non-A, non-B hepatitis]. ( Fujimoto, H; Fukuhara, T; Hashino, S; Imamura, M; Karino, Y; Kobayashi, H; Matsushima, T; Sakurada, K; Tanaka, M; Yoshida, J, 1989) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 13 (16.46) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (2.53) | 29.6817 |
2010's | 27 (34.18) | 24.3611 |
2020's | 37 (46.84) | 2.80 |
Authors | Studies |
---|---|
Thol, F | 1 |
Fan, B | 9 |
Chen, Y | 1 |
Yin, F | 1 |
Hua, L | 2 |
Almon, C | 2 |
Nabhan, S | 3 |
Cooper, M | 2 |
Yang, H | 7 |
Hossain, M | 1 |
Montesinos, P | 2 |
Recher, C | 1 |
Vives, S | 1 |
Zarzycka, E | 1 |
Wang, J | 1 |
Bertani, G | 1 |
Heuser, M | 1 |
Calado, RT | 1 |
Schuh, AC | 2 |
Yeh, SP | 1 |
Daigle, SR | 1 |
Hui, J | 1 |
Pandya, SS | 1 |
Gianolio, DA | 2 |
de Botton, S | 9 |
Döhner, H | 4 |
Liu, C | 1 |
Zou, W | 1 |
Nie, D | 1 |
Li, S | 1 |
Duan, C | 1 |
Zhou, M | 1 |
Lai, P | 1 |
Yang, S | 1 |
Ji, S | 1 |
Li, Y | 1 |
Mei, M | 1 |
Bao, S | 1 |
Jin, Y | 1 |
Pan, J | 1 |
Killock, D | 1 |
Gil-Sierra, MD | 1 |
Briceño-Casado, MP | 1 |
Sierra-Sanchez, JF | 1 |
Goodman, AM | 1 |
Mohyuddin, GR | 1 |
Prasad, V | 1 |
Reinbold, R | 1 |
Hvinden, IC | 1 |
Rabe, P | 1 |
Herold, RA | 1 |
Finch, A | 1 |
Wood, J | 1 |
Morgan, M | 1 |
Staudt, M | 1 |
Clifton, IJ | 1 |
Armstrong, FA | 1 |
McCullagh, JSO | 1 |
Redmond, J | 1 |
Bardella, C | 1 |
Abboud, MI | 1 |
Schofield, CJ | 1 |
Takahashi, K | 3 |
Kucukyurt, S | 1 |
Eskazan, AE | 1 |
Hosono, N | 1 |
DiNardo, CD | 10 |
Wei, AH | 2 |
Roboz, GJ | 4 |
Stein, EM | 6 |
Mims, AS | 4 |
Prince, GT | 2 |
Altman, JK | 4 |
Arellano, ML | 2 |
Donnellan, W | 2 |
Erba, HP | 3 |
Mannis, GN | 3 |
Pollyea, DA | 4 |
Stein, AS | 4 |
Uy, GL | 3 |
Watts, JM | 3 |
Fathi, AT | 5 |
Kantarjian, HM | 6 |
Tallman, MS | 5 |
Choe, S | 6 |
Dai, D | 4 |
Wang, H | 5 |
Zhang, V | 4 |
Yen, KE | 2 |
Kapsalis, SM | 3 |
Hickman, D | 2 |
Liu, H | 7 |
Agresta, SV | 2 |
Wu, B | 7 |
Attar, EC | 4 |
Stone, RM | 5 |
Estey, E | 2 |
Karp, JE | 1 |
Emadi, A | 1 |
Othus, M | 1 |
Gale, RP | 1 |
Pasquier, F | 1 |
Lecuit, M | 1 |
Broutin, S | 1 |
Saada, S | 1 |
Jeanson, A | 1 |
Penard-Lacronique, V | 1 |
Griffiths, EA | 1 |
Carraway, HE | 1 |
Chandhok, NS | 1 |
Prebet, T | 1 |
Stein, E | 1 |
Liu, G | 5 |
Lemieux, I | 1 |
Quek, L | 1 |
Konteatis, Z | 1 |
Dang, L | 1 |
Nicolay, B | 1 |
Nejad, P | 1 |
Goldwasser, M | 3 |
Liu, W | 1 |
Marks, K | 1 |
Bowden, C | 2 |
Biller, SA | 1 |
Norsworthy, KJ | 2 |
Mulkey, F | 1 |
Scott, EC | 1 |
Ward, AF | 1 |
Przepiorka, D | 2 |
Charlab, R | 2 |
Dorff, SE | 2 |
Deisseroth, A | 2 |
Kazandjian, D | 1 |
Sridhara, R | 1 |
Beaver, JA | 1 |
Farrell, AT | 2 |
de Claro, RA | 1 |
Pazdur, R | 2 |
Navada, SC | 2 |
Garcia-Manero, G | 2 |
OdchimarReissig, R | 1 |
Pemmaraju, N | 1 |
Alvarado, Y | 1 |
Ohanian, MN | 1 |
John, RB | 1 |
Demakos, EP | 2 |
Zbyszewski, PS | 2 |
Maniar, M | 2 |
Woodman, RC | 1 |
Fruchtman, SM | 2 |
Silverman, LR | 3 |
Zeidner, JF | 1 |
Tabata, MM | 1 |
Chase, M | 1 |
Kwong, BY | 1 |
Novoa, RA | 1 |
Fernandez-Pol, S | 1 |
Jeng, MY | 1 |
Dutta, R | 1 |
Tan, IT | 1 |
Zhang, TY | 1 |
Donker, ML | 1 |
Ossenkoppele, GJ | 3 |
Martelli, MP | 1 |
Martino, G | 1 |
Cardinali, V | 1 |
Falini, B | 1 |
Martinelli, G | 2 |
Cerchione, C | 1 |
Prakash, C | 3 |
Ke, A | 2 |
Le, K | 2 |
Pratz, KW | 1 |
Savona, MR | 1 |
Winer, ES | 1 |
Seet, CS | 1 |
McCloskey, JK | 1 |
Odenike, O | 1 |
Löwenberg, B | 2 |
Patel, PA | 2 |
Roshal, M | 1 |
Frattini, MG | 2 |
Lersch, F | 2 |
Franovic, A | 2 |
Visani, G | 1 |
Loscocco, F | 1 |
Dennis, M | 2 |
Zuffa, E | 1 |
Candoni, A | 1 |
Sensi, A | 1 |
Giannini, B | 1 |
Musuraca, G | 1 |
Mianulli, AM | 1 |
Clavio, M | 1 |
Rocchi, M | 1 |
Gibellini, D | 1 |
Navari, M | 1 |
Gilkes, A | 1 |
Piccaluga, PP | 1 |
Isidori, A | 1 |
Frankfurt, O | 2 |
Raffoux, E | 1 |
Tan, P | 1 |
Zeidan, AM | 1 |
Gong, J | 1 |
Daigle, S | 1 |
Winkler, T | 2 |
Vyas, P | 1 |
Xiao, W | 1 |
Miles, LA | 1 |
Bowman, RL | 1 |
Durani, V | 1 |
Tian, HS | 1 |
DelGaudio, NL | 1 |
Mishra, T | 1 |
Zhu, M | 1 |
Zhang, Y | 1 |
Stump, SE | 1 |
Levine, RL | 1 |
Cai, SF | 1 |
Jiang, X | 1 |
Wada, R | 1 |
Poland, B | 1 |
Kleijn, HJ | 1 |
Kapsalis, S | 1 |
Pigneux, A | 2 |
Collins, R | 1 |
Roeten, MSF | 1 |
van Meerloo, J | 1 |
Kwidama, ZJ | 1 |
Ter Huizen, G | 1 |
Segerink, WH | 1 |
Zweegman, S | 2 |
Kaspers, GJL | 1 |
Jansen, G | 1 |
Cloos, J | 1 |
Bolleddula, J | 1 |
Burnett, A | 2 |
Hills, R | 1 |
Thomas, I | 1 |
Ariti, C | 1 |
Severinsen, MT | 1 |
Hemmaway, C | 1 |
Greaves, P | 1 |
Clark, RE | 1 |
Copland, M | 1 |
Russell, N | 1 |
Wang, F | 1 |
Morita, K | 1 |
Furudate, K | 1 |
Tanaka, T | 1 |
Yan, Y | 1 |
Patel, KP | 1 |
MacBeth, KJ | 1 |
Frattini, M | 1 |
Matthews, JA | 1 |
Little, LD | 1 |
Gumbs, C | 1 |
Song, X | 1 |
Zhang, J | 1 |
Thompson, EJ | 1 |
Kadia, TM | 1 |
Jabbour, E | 1 |
Ravandi, F | 2 |
Bhalla, KN | 1 |
Konopleva, M | 2 |
Andrew Futreal, P | 1 |
Odchimar-Reissig, R | 1 |
Petrone, ME | 1 |
Holland, JF | 2 |
Swords, R | 1 |
Collins, RH | 1 |
Foran, JM | 1 |
Traer, E | 1 |
Stuart, RK | 1 |
Slack, JL | 1 |
Sekeres, MA | 2 |
Willekens, C | 1 |
Agresta, S | 2 |
Sidaway, P | 1 |
Khan, I | 1 |
Halasi, M | 1 |
Patel, A | 1 |
Schultz, R | 1 |
Kalakota, N | 1 |
Chen, YH | 1 |
Aardsma, N | 1 |
Liu, L | 1 |
Crispino, JD | 1 |
Mahmud, N | 1 |
Gartel, AL | 1 |
Dhillon, S | 1 |
Talati, C | 1 |
Sweet, K | 1 |
Aschenbrenner, DS | 1 |
Luo, L | 1 |
Hsu, V | 1 |
Gudi, R | 1 |
Shen, YL | 1 |
Sheth, CM | 1 |
Williams, GM | 1 |
Goldberg, KB | 1 |
Tiong, IS | 1 |
Advani, AS | 1 |
Cooper, B | 1 |
Visconte, V | 1 |
Elson, P | 1 |
Chan, R | 1 |
Carew, J | 1 |
Wei, W | 1 |
Mukherjee, S | 1 |
Gerds, A | 1 |
Carraway, H | 1 |
Nazha, A | 1 |
Hamilton, B | 1 |
Sobecks, R | 1 |
Caimi, P | 1 |
Tomlinson, B | 1 |
Malek, E | 1 |
Little, J | 1 |
Miron, A | 1 |
Pink, J | 1 |
Maciejewski, J | 1 |
Unger, A | 1 |
Kalaycio, M | 1 |
de Lima, M | 1 |
Zacher, J | 1 |
Vutikullird, A | 1 |
Guerra, VA | 1 |
DiNardo, C | 1 |
Hernandez Burgos, P | 1 |
Patel, J | 1 |
Chen, A | 1 |
Cortes, JE | 1 |
Kovarik, ML | 1 |
Dickinson, AJ | 1 |
Roy, P | 1 |
Poonnen, RA | 1 |
Fine, JP | 1 |
Allbritton, NL | 1 |
Greenberg, P | 1 |
Raza, A | 1 |
Olnes, MJ | 1 |
Reddy, P | 1 |
Wilhelm, F | 1 |
El-Ghany, HM | 1 |
El-Saadany, ZA | 1 |
Bahaa, NM | 1 |
Ibrahim, NY | 1 |
Hussien, SM | 1 |
Sachs, Z | 1 |
LaRue, RS | 1 |
Nguyen, HT | 1 |
Sachs, K | 1 |
Noble, KE | 1 |
Mohd Hassan, NA | 1 |
Diaz-Flores, E | 1 |
Rathe, SK | 1 |
Sarver, AL | 1 |
Bendall, SC | 1 |
Ha, NA | 1 |
Diers, MD | 1 |
Nolan, GP | 1 |
Shannon, KM | 1 |
Largaespada, DA | 1 |
Mawad, R | 1 |
Becker, PS | 1 |
Hendrie, P | 1 |
Scott, B | 1 |
Wood, BL | 1 |
Dean, C | 1 |
Sandhu, V | 1 |
Deeg, HJ | 1 |
Walter, R | 1 |
Wang, L | 1 |
Myint, H | 1 |
Singer, JW | 1 |
Pagel, JM | 1 |
Garcia, JS | 1 |
Huang, M | 1 |
Medeiros, BC | 1 |
Mitchell, BS | 1 |
Morgan, G | 1 |
Burnett, AK | 1 |
Zachée, P | 1 |
Dührsen, U | 1 |
Dierickx, D | 1 |
Müller-Tidow, C | 1 |
Sonneveld, P | 1 |
Krug, U | 1 |
Bone, E | 1 |
Flores, N | 1 |
Richardson, AF | 1 |
Hooftman, L | 1 |
Jenkins, C | 2 |
Davies, F | 1 |
Hewamana, S | 1 |
Krige, D | 1 |
Pepper, C | 1 |
Shi, J | 1 |
Wang, E | 1 |
Zuber, J | 1 |
Rappaport, A | 1 |
Taylor, M | 1 |
Johns, C | 1 |
Lowe, SW | 1 |
Vakoc, CR | 1 |
Mathisen, MS | 1 |
Szer, J | 1 |
Bacher, U | 1 |
Haferlach, T | 1 |
Schoch, C | 1 |
Kern, W | 1 |
Schnittger, S | 1 |
Kien, CL | 1 |
Camitta, BM | 1 |
Choi, CH | 1 |
Kim, HS | 1 |
Kweon, OS | 1 |
Lee, TB | 1 |
You, HJ | 1 |
Rha, HS | 1 |
Jeong, JH | 1 |
Lim, DY | 1 |
Min, YD | 1 |
Kim, MS | 1 |
Chung, MH | 1 |
Palma-Carlos, AG | 1 |
Palma-Carlos, L | 1 |
Lourenço, G | 1 |
Loeper, J | 1 |
Cottet, J | 1 |
Debray, J | 1 |
Taylor, GM | 1 |
Freeman, CB | 1 |
Harris, R | 1 |
Hashino, S | 1 |
Imamura, M | 1 |
Kobayashi, H | 1 |
Tanaka, M | 1 |
Fukuhara, T | 1 |
Fujimoto, H | 1 |
Karino, Y | 1 |
Yoshida, J | 1 |
Sakurada, K | 1 |
Matsushima, T | 1 |
Miura, K | 1 |
Sawa, T | 1 |
Takeuchi, T | 1 |
Umezawa, H | 1 |
Kotlarek-Haus, S | 1 |
Eastman, PM | 1 |
Schwartz, R | 1 |
Schrier, SL | 1 |
Walters, TR | 1 |
Welland, FH | 1 |
Gribble, TJ | 1 |
Schwartz, HC | 1 |
Takaku, F | 1 |
Wada, O | 1 |
Sassa, S | 1 |
Nakao, K | 1 |
Rosa, J | 1 |
Beuzard, Y | 1 |
Brun, B | 1 |
Toulgoat, N | 1 |
Cerný, V | 1 |
Dimitrov, NV | 1 |
Hansz, J | 1 |
Toth, MA | 1 |
Bartolotta, B | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation[NCT02632708] | Phase 1 | 153 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation[NCT03173248] | Phase 3 | 146 participants (Actual) | Interventional | 2017-06-26 | Active, not recruiting | ||
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation[NCT02074839] | Phase 1 | 291 participants (Anticipated) | Interventional | 2014-03-31 | Recruiting | ||
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia[NCT01926587] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute [NCT02677922] | Phase 1/Phase 2 | 130 participants (Actual) | Interventional | 2016-06-03 | Active, not recruiting | ||
Phase I Dose Escalation Study of ON 01910.Na With Increasing Duration of an Initial 3-Day Continuous Infusion in Patients With Refractory Leukemia or MDS[NCT00854646] | Phase 1 | 22 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
A Phase I, First in Human, Open-label Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia[NCT03957915] | Early Phase 1 | 34 participants (Anticipated) | Interventional | 2020-05-29 | Recruiting | ||
Efficacy and Safety of Ambulatory Low-dose Venetoclax and Azacitidne as First Line Therapy in Newly Diagnosed AML: a Pilot Study[NCT05048615] | Phase 2 | 15 participants (Actual) | Interventional | 2021-07-26 | Completed | ||
Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine[NCT01928537] | Phase 3 | 67 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
A Phase 2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-1, 2 or High Risk[NCT00906334] | Phase 2 | 14 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
A Phase I-II Study to Evaluate the Safety, Tolerability and Anti-Disease Activity of the Aminopeptidase Inhibitor, CHR-2797, in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia or Multiple Myeloma[NCT00689000] | Phase 1/Phase 2 | 57 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
EFS was defined as the time from randomization until treatment failure, relapse from remission, or death from any cause, whichever occurs first. Treatment failure was defined as failure to achieve complete remission (CR) by Week 24. CR: Bone marrow blasts <5% and no Auer rods; absence of extramedullary disease; Absolute neutrophil count (ANC) ≥1.0 × 10^9 per litre (10^9/L) (1000 per microlitre [1000/μL]); platelet count ≥100 × 10^9/L (100,000/μL); independence of red blood cell transfusions. Participants who had an EFS event (relapse or death) after, 2 or more missing disease assessments were censored at the last adequate disease assessment documenting no relapse before the missing assessments. The reported data represents the Kaplan-Meier median value. (NCT03173248)
Timeframe: Up to Week 24
Intervention | months (Median) |
---|---|
AG-120 + Azacitidine | 0.03 |
Placebo + Azacitidine | 0.03 |
AUC0-24: Area under the plasma concentration-time curve from time zero to 24 hours, calculated using the linear trapezoid rule. (NCT02677922)
Timeframe: Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2
Intervention | (h*ng/mL) (Mean) |
---|---|
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 285864.2637 |
Area under the plasma concentration-time curve from time zero to 8 hours, calculated using the linear trapezoid rule. (NCT02677922)
Timeframe: Pre-dose, 2, 3, 4, 6, and 8 hours post dose (± 10 minutes) on day 1 of cycle 2
Intervention | (h*ng/mL) (Mean) |
---|---|
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 100302.8231 |
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. These health states are converted to a single index value using the crosswalk method to the EQ-5D-3L value set from the United Kingdom (UK). The EQ-5D-3L health utility index based on the UK population weights range from -0.594 to 1.0 with higher scores indicating higher health utility. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values. (NCT02677922)
Timeframe: Baseline and Day 1 Cycle 5
Intervention | Score on a scale (Mean) |
---|---|
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 0.04 |
Phase 2 Randomized Stage: AZA Monotherapy | 0.02 |
"The European Quality of Life 5D-5L (EQ-5D-5L) instrument has a respondent's self-rated today's health scale which is recorded on a VAS with endpoints labeled the best health you can imagine and the worst health you can imagine. The scale is numbered from 0 to 100 with 0 corresponding to the worst imaginable health state and 100 corresponding to the best imaginable health state. A high score represents a better level of QoL. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values." (NCT02677922)
Timeframe: Baseline and Day 1 Cycle 5
Intervention | Score on a scale (Mean) |
---|---|
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 13.00 |
Phase 2 Randomized Stage: AZA Monotherapy | 1.65 |
Cmax: Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. (NCT02677922)
Timeframe: Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2
Intervention | (ng/mL) (Mean) |
---|---|
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 15965.0 |
The percent of participants with morphologic complete remission (CR) according to modified International Working Group Acute Myeloid Leukemia Response Criteria (IWG AML). CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease; plus the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. (NCT02677922)
Timeframe: From first dose up to approximately 26 months
Intervention | Percent of Participants (Number) |
---|---|
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 54.4 |
Phase 2 Randomized Stage: AZA Monotherapy | 12.1 |
The time from first documented CR/CRi/CRp/PR/MLFS to documented morphologic relapse, progression, or death due to any cause, whichever occurred first. CR and MLFS are defined as <5% blasts in a BM aspirate sample with marrow spicules + a count of ≥200 nucleated cells with no blasts with Auer rods + no extramedullary disease. CR must also include: ANC ≥ 1,000/μL, Platelet count ≥100,000/μL, + independent of red cell transfusions for ≥1 week before assessment. CRi is all criteria of CR except ANC. CRp is all criteria of CR except platelet count. PR is defined as all hematologic criteria of CR with >50% decrease in BM blasts to 5%-25%. Relapse is defined as reappearance of ≥ 5% blasts in the BM not attributable to other cause or development of extramedullary disease. Progression is defined as > 50% increase of BM blast count from baseline to ≥ 20% or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10,000/μL or development of new extramedullary disease. (NCT02677922)
Timeframe: From first dose up to approximately 26 months
Intervention | Months (Median) |
---|---|
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 24.1 |
Phase 2 Randomized Stage: AZA Monotherapy | 9.9 |
Event-Free Survival is the time from date of randomization to the date of documented morphologic relapse, progression, or death from any cause, whichever occurs first. Morphologic Relapse is defined as either reappearance of ≥ 5% blasts in the BM not attributable to any other cause or the development of extramedullary disease. Progression is defined as a > 50% increase of BM blast count percentage from baseline to ≥ 20% for participants with 5 to 70% BM blasts at baseline or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10 x 109/L (10,000/μL) for participants with > 70% BM blasts at baseline or the development of new extramedullary disease. (NCT02677922)
Timeframe: From randomization to the date of documented relapse, progression, or death due to any cause, whichever occurs first (up to approximately 26 months)
Intervention | Months (Median) |
---|---|
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 15.9 |
Phase 2 Randomized Stage: AZA Monotherapy | 11.9 |
The percent of participants with hematologic improvement neutrophil response (HI-N) + hematologic improvement platelet response (HI-P) + hematologic improvement erythroid response (HI-E) according to the International Working Group for Myelodysplastic Syndromes for Hematologic Improvement (IWG MDS HI) criteria. HI-E is defined as a hemoglobin increase by ≥ 1.5 g/dL and a relevant reduction in units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 week compared with the pretreatment transfusion number in the previous 8 week. HI-P is defined as an absolute increase of ≥ 30 X 10^9/L for participants starting with > 20 X and an increase from < 20 X 10^9/L to > 20 X 10^9/L and by at least 100%. HI-N is defined as At least 100% increase and an absolute increase > 0.5 X 10^9/L. (NCT02677922)
Timeframe: From first dose up to approximately 26 months
Intervention | Percent of Participants (Number) |
---|---|
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 70.6 |
Phase 2 Randomized Stage: AZA Monotherapy | 57.6 |
The percent of participants alive at 1 year from randomization (NCT02677922)
Timeframe: From randomization to 1 year after randomization
Intervention | Percent of Participants (Number) |
---|---|
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 72.2 |
Phase 2 Randomized Stage: AZA Monotherapy | 69.6 |
Percent of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria as assessed by investigator. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as <5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a >50% decrease in the percentage of BM blasts to 5% to 25%. (<5% considered if Auer rods are present). (NCT02677922)
Timeframe: From first dose up to approximately 13 months
Intervention | Percent of Participants (Number) |
---|---|
Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | 66.7 |
Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | 66.7 |
Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | 100 |
Phase 1b Expansion Stage: AG-120 (500mg) + AZA | 68.8 |
The percent of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria as assessed by investigator. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as <5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a >50% decrease in the percentage of BM blasts to 5% to 25%. (<5% considered if Auer rods are present). (NCT02677922)
Timeframe: From first dose up to approximately 26 months
Intervention | Percent of Participants (Number) |
---|---|
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 73.5 |
Phase 2 Randomized Stage: AZA Monotherapy | 36.4 |
Overall survival (OS) is defined as time from randomization to death due to any cause. (NCT02677922)
Timeframe: From randomization to date of death (up to approximately 26 months)
Intervention | Months (Median) |
---|---|
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 22.0 |
Phase 2 Randomized Stage: AZA Monotherapy | 22.3 |
The percent of participants with morphologic complete remission (CR) and morphologic complete remission with partial hematologic recovery (CRh) based on laboratory data. CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment. CRh is defined as less than 5% blasts in a BM aspirate sample with marrow spicules plus ANC > 500 x 109/L (1,000/μL) & Platelet count > 50 x 109/L (100,000/μL). CRh is defined as Response of bone marrow blast <5% with absolute neutrophil count (ANC) > 0.5 × 10^9/L and platelet > 50 × 10^9/L. (NCT02677922)
Timeframe: From first dose up to approximately 13 months
Intervention | Percent of Participants (Number) |
---|---|
Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | 66.7 |
Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | 66.7 |
Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | 71.4 |
Phase 1b Expansion Stage: AG-120 (500mg) + AZA | 62.5 |
Dose-limiting toxicities (DLTs) are defined as an event that constitute a change from baseline irrespective of outcome and determined by the investigator to be related to treatment. The DLT-evaluable participants were defined as participants who took at least 1 dose of study drug in the Phase 1b Dose-Finding Stage and either had a DLT during Cycle 1 (regardless of amount of study drug exposure), or had no DLT and completed at least 75% of AG-120 or AG-221 doses (21 out of 28 days) and a minimum of 5 doses of AZA, at least 50% of the planned combination doses for AG-120 or AG-221 and AZA administered together (in the same day for 4 out of 7 days) in the first 28 days from C1D1, and were also considered by the Clinical Study Team to have sufficient safety data available to conclude that a DLT did not occur during Cycle 1. (NCT02677922)
Timeframe: From first dose to 28 days after first dose
Intervention | Participants (Count of Participants) |
---|---|
Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | 0 |
Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | 0 |
Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | 0 |
Time from first dose of study drug to first documented MLFS/CR/CRi/CRp/PR according to modified IWG AML response criteria. Complete remission (CR) and morphologic leukemia-free state (MLFS) are defined as <5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. partial remission (PR) is defined as all hematologic criteria of CR with a >50% decrease in the percentage of BM blasts to 5% to 25%. (<5% considered if Auer rods are present). (NCT02677922)
Timeframe: From first dose to to first documented MLFS/CR/CRi/CRp/PR (up to approximately 26 months)
Intervention | Months (Mean) |
---|---|
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 3.05 |
Phase 2 Randomized Stage: AZA Monotherapy | 3.42 |
Tmax: Time of maximum observed plasma concentration, obtained directly from the observed concentration versus time data. (NCT02677922)
Timeframe: Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2
Intervention | (h) (Median) |
---|---|
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 2.5333 |
Area under the plasma concentration-time curve from time zero to 8 hours, calculated using the linear trapezoid rule. (NCT02677922)
Timeframe: Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2
Intervention | (h*ng/mL) (Mean) | |
---|---|---|
CYCLE 1 DAY 1 | CYCLE 2 DAY 1 | |
Phase 1b Expansion Stage: AG-120 (500mg) + AZA | 31952.4465 | 44291.5504 |
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is composed of 30 items that address general physical symptoms, physical functioning, fatigue and malaise, and social and emotional functioning. Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values. EORTC QLQ-C30 is assessed prior to dosing and prior to interaction with study personnel. (NCT02677922)
Timeframe: Baseline and Day 1 Cycle 5
Intervention | Score on a scale (Mean) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Global QoL | Physical functioning | Role functioning | Cognitive functioning | Emotional functioning | Social functioning | Fatigue | Nausea and vomiting | Pain | Dyspnea | Insomnia | Appetite loss | Constipation | Diarrhea | Financial difficulties | |
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 12.2 | 1.9 | -0.6 | -4.8 | 7.7 | -6.5 | -17.5 | -6.0 | -13.1 | -27.4 | -6.0 | -7.1 | 6.0 | -7.1 | 8.3 |
Phase 2 Randomized Stage: AZA Monotherapy | 4.9 | 6.7 | 1.0 | 4.9 | 8.8 | 6.9 | -8.5 | 1.0 | -4.9 | -9.8 | -13.7 | -5.9 | -9.8 | -5.9 | -2.0 |
Cmax: Maximum observed plasma concentration, obtained directly from the observed concentration versus time data (NCT02677922)
Timeframe: Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2
Intervention | (ng/mL) (Mean) | |
---|---|---|
CYCLE 1 DAY 1 | CYCLE 2 DAY 1 | |
Phase 1b Expansion Stage: AG-120 (500mg) + AZA | 6058.0 | 6340.7 |
The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or constitutes an important medical event. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). Treatment-emergent adverse events (TEAE) was defined as events that began on or after the start of study drug through 28 days after the last study treatment. The severity/intensity of AEs were graded based upon the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) where Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death. (NCT02677922)
Timeframe: From first dose to 28 days after last dose (up to approximately 13 months)
Intervention | Participants (Count of Participants) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Participants with at Least One TEAE | Participants with at Least One TEAE Related to Study Drug(s) | Participants with at Least One Grade 3-4 TEAE | Participants with at least One Grade 3-4 TEAE Related to Study Drug(s) | Participants with at Least One Grade 5 TEAE | Participants with at Least One Grade 5 TEAE Related to Study Drug(s) | Participants with at Least One Serious TEAE | Participants with at Least One Serious TEAE Related to Study Drug(s) | Participants with at Least One TEAE Leading to Discontinuation of Study Drug(s) | Participants with at Least One Study Drug Related TEAE Leading to Discontinuation of Study Drug | Participants with at Least One TEAE Leading to Dose Reduction of Study Drug(s) | Participants with at Least One TEAE Leading to Dose Interruption of Study Drug(s) | Participants with at Least One Study Drug(s) Related TEAE Leading to Study Drug Dose Reduction | Participants with at Least One Study Drug(s) Related TEAE Leading to Study Drug Dose Interruption | |
Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | 7 | 7 | 7 | 4 | 1 | 0 | 4 | 1 | 1 | 0 | 2 | 2 | 1 | 2 |
Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | 3 | 3 | 3 | 2 | 0 | 0 | 3 | 0 | 1 | 0 | 1 | 3 | 0 | 1 |
Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | 3 | 3 | 3 | 2 | 1 | 0 | 2 | 1 | 0 | 0 | 1 | 3 | 1 | 2 |
Phase 1b Expansion Stage: AG-120 (500mg) + AZA | 16 | 16 | 15 | 10 | 2 | 0 | 11 | 5 | 4 | 1 | 5 | 11 | 5 | 8 |
The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or constitutes an important medical event. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). Treatment-emergent adverse events (TEAE) was defined as events that began on or after the start of study drug through 28 days after the last study treatment. The severity/intensity of AEs were graded based upon the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) where Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death. (NCT02677922)
Timeframe: From first dose to 28 days after last dose (up to approximately 26 months)
Intervention | Participants (Count of Participants) | |||||||
---|---|---|---|---|---|---|---|---|
Participants with at Least One TEAE | Participants with at Least One TEAE Related to Study Drug(s) | Participants with at Least One Grade 3-4 TEAE | Participants with at least One Grade 3-4 TEAE Related to Study Drug(s) | Participants with at Least One Grade 5 TEAE | Participants with at Least One Grade 5 TEAE Related to Study Drug(s) | Participants with at Least One Serious TEAE | Participants with at Least One Serious TEAE Related to Study Drug(s) | |
Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 68 | 62 | 68 | 50 | 15 | 0 | 64 | 29 |
Phase 2 Randomized Stage: AZA Monotherapy | 32 | 26 | 31 | 20 | 2 | 0 | 25 | 14 |
Tmax: Time of maximum observed plasma concentration, obtained directly from the observed concentration versus time data. (NCT02677922)
Timeframe: Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2
Intervention | (h) (Median) | |
---|---|---|
CYCLE 1 DAY 1 | CYCLE 2 DAY 1 | |
Phase 1b Expansion Stage: AG-120 (500mg) + AZA | 3.0000 | 2.5000 |
15 reviews available for glycine and Leukemia, Myeloid, Acute
Article | Year |
---|---|
New drugs approved for acute myeloid leukaemia in 2018.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; C | 2019 |
[New therapeutic agents for acute myeloid leukemia].
Topics: Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cyclopentanes; Drug Approval; Flavonoids; G | 2019 |
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Topics: Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorub | 2020 |
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo C | 2020 |
Evaluating ivosidenib for the treatment of acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Glycine; H | 2020 |
Enasidenib and ivosidenib in AML.
Topics: Aminopyridines; Antineoplastic Agents; Cell Differentiation; Clinical Trials as Topic; Glutarates; G | 2020 |
Ivosidenib: First Global Approval.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Drug Approval; Enzyme Inhibitors; Epigenesis, Genetic | 2018 |
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Cytarabine; Daunorubicin; Female | 2018 |
New drugs creating new challenges in acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; | 2019 |
Venetoclax-based therapies for acute myeloid leukemia.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Comp | 2019 |
Ivosidenib induction therapy complicated by myopericarditis and cardiogenic shock: A case report and literature review.
Topics: Adult; Female; Glycine; Humans; Leukemia, Myeloid, Acute; Mutation; Myocarditis; Pyridines; Recurren | 2020 |
Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Glycine; Humans; Hydroxamic Acids; Leukem | 2014 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aminopeptidases; Antineoplastic Agents; Antineoplasti | 2012 |
The prevalent predicament of relapsed acute myeloid leukemia.
Topics: Adenine Nucleotides; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Arabinonucleos | 2012 |
16 trials available for glycine and Leukemia, Myeloid, Acute
Article | Year |
---|---|
Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.
Topics: Adult; Aminopyridines; Antineoplastic Agents; Consolidation Chemotherapy; Glycine; Humans; Isocitrat | 2022 |
Ivosidenib and Azacitidine in
Topics: Antineoplastic Agents; Azacitidine; Febrile Neutropenia; Glycine; Humans; Isocitrate Dehydrogenase; | 2022 |
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Blood Transfusion; Female; Glycine; Humans; Isocitrate Dehydrogenase; Leuke | 2020 |
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
Topics: Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Mo | 2020 |
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Glycine; Humans; Leukemia, Myelogenous, Chronic | 2020 |
Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies.
Topics: Aged, 80 and over; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2020 |
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Female; Glycine; Humans; Isocitrate Dehydrogenas | 2021 |
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Apoptosis; Azacitidine; Drug Therapy, Combination; Enzyme Inhibitors; Femal | 2021 |
Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under | 2021 |
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2021 |
A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Dru | 2018 |
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Cell Count; Dose-Response Relation | 2018 |
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Cell Count; Dose-Response Relation | 2018 |
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Cell Count; Dose-Response Relation | 2018 |
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Cell Count; Dose-Response Relation | 2018 |
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cytarabine; Drug Resis | 2019 |
Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Asian People; Cross-Over Studi | 2019 |
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; De | 2016 |
Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.
Topics: Adult; Aged; Aged, 80 and over; Aminopeptidases; Female; Glycine; Humans; Hydroxamic Acids; Leukemia | 2010 |
48 other studies available for glycine and Leukemia, Myeloid, Acute
Article | Year |
---|---|
What to use to treat AML: the role of emerging therapies.
Topics: Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Appro | 2021 |
Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML.
Topics: Animals; Epigenesis, Genetic; Glycine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, M | 2022 |
Ivosidenib Boosts OS with Azacitidine in AML.
Topics: Azacitidine; Glycine; Humans; Leukemia, Myeloid, Acute; Pyridines | 2022 |
Ivosidenib combination improves OS.
Topics: Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines | 2022 |
Ivosidenib and Azacitidine in IDH1-Mutated AML.
Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines | 2022 |
Ivosidenib and Azacitidine in IDH1-Mutated AML.
Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines | 2022 |
Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.
Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines | 2022 |
Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors.
Topics: Drug Resistance, Neoplasm; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Muta | 2022 |
Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia?
Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridine | 2023 |
Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia?
Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridine | 2023 |
Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia?
Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridine | 2023 |
Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia?
Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridine | 2023 |
How I treat acute myeloid leukemia in the era of new drugs.
Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bi | 2020 |
Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Enzyme Inhibitors; Epigenesis, Genetic; Glycine; Humans; Isocitr | 2020 |
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Topics: Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines; Recurrence | 2020 |
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
Topics: Aminopyridines; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyrid | 2020 |
Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML.
Topics: Aminopyridines; Cell Differentiation; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, | 2020 |
Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation.
Topics: Aged; Antineoplastic Agents; Diagnosis, Differential; Glycine; Humans; Immunohistochemistry; Isocitr | 2020 |
Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Computer Simulation; Cytochrome P-450 | 2020 |
Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Glycine; Humans; Hydroxamic Acids; | 2020 |
A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN.
Topics: Clone Cells; Glycine; Humans; Isocitrate Dehydrogenase; Janus Kinase 2; Leukemia, Myeloid, Acute; Py | 2020 |
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Fo | 2021 |
Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Topics: Boron Compounds; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycine; Humans; Leukemia, | 2021 |
PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Caco-2 Cells; Cytochrome P-450 CYP3A | 2021 |
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Topics: Aged; Aminopyridines; Antineoplastic Agents; CCAAT-Enhancer-Binding Proteins; Core Binding Factor Al | 2021 |
Ivosidenib effective in IDH1-mutant AML.
Topics: Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines | 2018 |
Ivosidenib Deemed Safe, Effective in AML.
Topics: Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridines | 2018 |
FOXM1 contributes to treatment failure in acute myeloid leukemia.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cell Line, Tumor; Ce | 2018 |
First Drug Approved for Patients with Refractory AML and Mutation in the IDH1 Gene.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Antineoplastic Agents; Female; Glycine; Humans; | 2018 |
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
Topics: Antineoplastic Agents; Drug Approval; Enzyme Inhibitors; Glycine; Humans; Isocitrate Dehydrogenase; | 2019 |
Response of single leukemic cells to peptidase inhibitor therapy across time and dose using a microfluidic device.
Topics: Cell Survival; Dose-Response Relationship, Drug; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloi | 2014 |
Stromal cell derived factor-1 (CXCL12) chemokine gene variant in myeloid leukemias.
Topics: 3' Untranslated Regions; Adolescent; Adult; Aged; Alanine; Case-Control Studies; Chemokine CXCL12; F | 2014 |
NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.
Topics: Amino Acid Substitution; Animals; Cell Proliferation; Cell Transformation, Neoplastic; Disease Model | 2014 |
Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.
Topics: Antineoplastic Agents; Apoptosis; Boron Compounds; Cell Line, Tumor; Cell Survival; Cytoplasm; Flow | 2016 |
Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia.
Topics: Adult; Aminopeptidases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell | 2011 |
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.
Topics: Amino Acid Substitution; Animals; Aspartic Acid; Cell Proliferation; Disease Models, Animal; Genes, | 2013 |
Implications of NRAS mutations in AML: a study of 2502 patients.
Topics: Amino Acid Substitution; Asparagine; Chromosome Inversion; Codon; Gene Frequency; Genes, ras; Glycin | 2006 |
Increased whole-body protein turnover in sick children with newly diagnosed leukemia or lymphoma.
Topics: Ammonia; Glycine; Humans; Kinetics; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Nitrogen | 1983 |
Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines.
Topics: Alkynes; Antineoplastic Agents; Camptothecin; Cell Survival; Cisplatin; Daunorubicin; Dose-Response | 2000 |
[The effect of cyclophosphamide on haem synthesis in acute myeloblastic leukaemias (author's transl)].
Topics: Aminolevulinic Acid; Anemia, Sideroblastic; Coproporphyrins; Cyclophosphamide; Erythrocytes; Glycine | 1975 |
[Letter: Amino acids and leukemias].
Topics: Amino Acids; Cystine; Glycine; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Tryptophan | 1975 |
Response of remission lymphocytes to autochthonous leukaemic myeloblasts.
Topics: Antigens; Cell Membrane; Glycine; Humans; Leukemia, Myeloid, Acute; Lymphocyte Activation; Lymphocyt | 1976 |
[Allogeneic bone marrow transplantation after the treatment of alpha-IFN and high-dose SNMC in two cases of acute myeloblastic leukemia with post-transfusional non-A, non-B hepatitis].
Topics: Adult; Bone Marrow Transplantation; Combined Modality Therapy; Drug Therapy, Combination; Glycine; G | 1989 |
Effects of enzyme inhibitors in inhibiting the growth and inducing the differentiation of human promyelocytic leukemia cells, HL-60.
Topics: Anti-Bacterial Agents; Cell Differentiation; Cell Line; Enzyme Inhibitors; Glycine; Guanidines; Huma | 1986 |
[Behavior of aminopeptidase activity in human leukemic leukocytes].
Topics: Acyltransferases; Adolescent; Adult; Aged; Aminopeptidases; Aspartic Acid; Child; Clinical Enzyme Te | 1971 |
Distinctions between idiopathic ineffective erythropoiesis and di Guglielmo's disease: clinical and biochemical differences.
Topics: 5-Aminolevulinate Synthetase; Adult; Aged; Anemia, Hemolytic; Blood Cell Count; Blood Platelets; Bon | 1972 |
Biosynthesis of heme in leukemic leukocytes.
Topics: Adult; Animals; Glycine; Heme; Humans; Iron Isotopes; Leukemia; Leukemia, Lymphoid; Leukemia, Monocy | 1967 |
Heme synthesis in normal and leukemic leukocytes.
Topics: Carbon Isotopes; Glycine; Heme; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, M | 1968 |
Evidence of various types of synthesis of human gamma chains of haemoglobin in acquired haematological disorders.
Topics: Alanine; Anemia; Anemia, Sideroblastic; Blood Cell Count; Child, Preschool; Chromatography; Chromato | 1971 |
Preliminary clinical trial with a purine analogue butocine.
Topics: Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Bronchogenic; Drug Tolerance; Glycine; Humans | 1971 |
Serine and aspartic acid metabolism in leukemic leukocytes: correlation to effectiveness of therapy.
Topics: Adult; Aged; Aspartic Acid; Blood Proteins; Carbon Dioxide; Carbon Isotopes; Female; Glycine; Humans | 1971 |